Department of General Internal Medicine, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
Department of Anatomical Pathology, Hiroshima University Hospital, Hiroshima, Japan.
J Hepatobiliary Pancreat Sci. 2016 May;23(5):260-9. doi: 10.1002/jhbp.333. Epub 2016 Apr 4.
We previously reported a model of non-alcoholic fatty liver disease (NAFLD) using spontaneously hypertensive rats (SHRs), fed a choline-deficient (CD) diet for 5 weeks, that hepatic steatosis but not fibrosis is developed through oxidative stress. To determine the relationship between hypertension and hepatic fibrosis in NAFLD, we examined whether long-term CD diet leads to hepatic fibrosis through oxidative stress.
Eight-week-old male SHR and normotensive Wistar Kyoto rats (WKYs) were fed a CD diet for 5 or 20 weeks, then liver histology and hepatic expression of genes related to lipid metabolism, fibrosis, and oxidative stress were assessed. Oxidative stress was assessed by hepatic thiobarbituric acid reactive substance (TBARS) levels.
After 5 weeks on CD diet, prominent hepatic steatosis and decrease in expression of genes for lipid metabolism were observed in SHRs as compared with WKYs. SHRs on a CD diet demonstrated a downregulated expression of genes for antioxidants, along with significant increases in hepatic TBARS. After 20 weeks on CD diet, SHRs demonstrated severe liver fibrosis and upregulated expressions of genes for fibrosis when compared with WKY.
Hypertension precipitated hepatic steatosis, and further, acts as an enhancer in NAFLD progression to liver fibrosis through oxidative stress.
我们之前报道了一种非酒精性脂肪性肝病(NAFLD)模型,使用自发性高血压大鼠(SHRs),用胆碱缺乏(CD)饮食喂养 5 周,通过氧化应激发展肝脂肪变性,但不发展肝纤维化。为了确定 NAFLD 中高血压和肝纤维化之间的关系,我们研究了长期 CD 饮食是否通过氧化应激导致肝纤维化。
8 周龄雄性 SHR 和正常血压的 Wistar Kyoto 大鼠(WKYs)用 CD 饮食喂养 5 或 20 周,然后评估肝组织学和与脂质代谢、纤维化和氧化应激相关的基因在肝脏中的表达。通过肝硫代巴比妥酸反应物质(TBARS)水平评估氧化应激。
与 WKY 相比,SHR 在 CD 饮食 5 周后表现出明显的肝脂肪变性和脂质代谢基因表达减少。CD 饮食的 SHR 表现出抗氧化基因表达下调,同时肝 TBARS 显著增加。用 CD 饮食喂养 20 周后,与 WKY 相比,SHR 表现出严重的肝纤维化和纤维化基因表达上调。
高血压引发肝脂肪变性,并且通过氧化应激进一步作为 NAFLD 进展为肝纤维化的增强剂。